VEGFA and colorectal carcinoma: Bevacizumab (BEV), a monoclonal antibody against VEGF, was the first antiangiogenesis drug approved by the Food and Drug Administration (FDA) for use in advanced colorectal carcinoma (Hurwitz et al., 2004).